New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
80.00+0.05 (+0.06%)
At close: 04:00PM EST
80.06 +0.06 (+0.07%)
After hours: 07:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close79.95
Open80.62
Bid79.00 x 800
Ask81.00 x 1200
Day's range79.64 - 80.76
52-week range79.34 - 98.52
Volume2,364,688
Avg. volume2,136,500
Market cap178.967B
Beta (5Y monthly)0.53
PE ratio (TTM)18.48
EPS (TTM)4.33
Earnings dateN/A
Forward dividend & yield3.20 (4.00%)
Ex-dividend date04 Mar 2021
1y target est104.00
  • Zacks

    Novartis (NVS) Highlights Growth Profile at its R&D Day

    Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

  • Zacks

    Aurinia (AUPH) Stock Up on Potential Acquisition Rumors

    Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.

  • Motley Fool

    Why Aurinia Pharmaceuticals Stock Bolted Higher Today

    Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by a noteworthy 15.5% as of 1:10 p.m. ET Thursday afternoon. Rumors began to swirl about a possible buyout this morning after Novartis (NYSE: NVS) reportedly said during its research and development day that it will focus on smaller bolt-on acquisitions, instead of megadeals. Aurinia has repeatedly been the topic of the buyout rumor mill in 2021.